OUR SCIENCE

Xitra is leveraging Constant Therapeutic’s experience with TXA127 and Mas/MrgD receptor biology to develop small molecules targeting the same receptors as TXA127 and thus show the same beneficial effects in diseases, such as chronic stroke, Duchenne muscular dystrophy, or epithermolysis bullosa.

We are focused on establishing clinical proof of concept in core muscle-related indications and high value adjacent diseases.